Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q
Source: 0001731122-25-000258
Chunk: 100

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q
Item: Part I, Item 8
Chunk 100
---
 selection, (iii) prediction and tracking response to therapies, (iv) recurrence detection and efficacy monitoring,
and (v) ultimately, drug discovery.

Renovaro Cube was initially incorporated
as Grace Systems B.V. (“Grace Systems”) in 2013 under the laws of the Netherlands to develop unique data mining algorithms
to enable banking, finance and government entities to extract business insights from data. Grace Systems began applying its algorithms
to biological data in 2018 to uncover cancer-associated patterns. Beginning in 2018, Grace Systems pivoted its platform to focus only
on healthcare. Renovaro Cube has focused on developing its AI technology for early cancer detection.

Renovaro Cube has now focused on
commercialization of its AI technology. Renovaro Cube believes that it has developed a unique approach to the early detection and diagnosis
of cancer and its recurrence and, in time, other rare diseases through the systematic analysis of data using AI technologies, data mining
procedures and algorithms for health technology.

Renovaro Cube’s technology
has been trained on complex heterogeneous cancer data and appears to find patterns associated with cancer in public and private data resources.
With the help of Renovaro Cube’s algorithms, discovered patterns may be translated into biomarkers that can be used in a clinical
setting to target various aspects of cancer diagnosis and treatment.

Renovaro Cube’s Strategy

Renovaro Cube’s product development
focuses on four core areas:

    ●
    Early Detection. Multi-cancer early detection (“MCED”) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the bloodstream. These tests specifically look for abnormal genetic, epigenetic or proteomic patterns of these cell-derived molecules, which can indicate the presence of cancer cells. By examining the molecules shed from various cells, including cancer cells, MCED tests aim to detect cancer at an early stage. This approach holds promise for improving cancer detection and potentially saving lives.

    ●
    Recurrence of cancer. A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts to kill the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop a new cancer that’s completely unrelated to the originally diagnosed cancer, which is referred to as a second primary cancer. An early warning system could help to identify a recurrence as early as possible, thereby helping to accelerate any treatment and diagnosis. The different types of recurrence include:

25

    o